Lexicon Pharmaceuticals (LXRX) +12.5% premarket after revealing positive top-line results from a...

|About: Lexicon Pharmaceuticals, Inc. (LXRX)|By:, SA News Editor

Lexicon Pharmaceuticals (LXRX) +12.5% premarket after revealing positive top-line results from a midstage study for telotristat etiprate, its investigational new drug to treat carcinoid syndrome. The drug currently has fast track status and orphan drug designation from the FDA, and orphan drug designation from European regulators.